Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,457 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2.
Wahle BM, Hawley ET, He Y, Smith AE, Yuan J, Masters AR, Jones DR, Gehlhausen JR, Park SJ, Conway SJ, Clapp DW, Yates CW. Wahle BM, et al. Among authors: park sj. Oncotarget. 2017 Oct 24;9(1):718-725. doi: 10.18632/oncotarget.22002. eCollection 2018 Jan 2. Oncotarget. 2017. PMID: 29416648 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33685622
A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.
Gehlhausen JR, Park SJ, Hickox AE, Shew M, Staser K, Rhodes SD, Menon K, Lajiness JD, Mwanthi M, Yang X, Yuan J, Territo P, Hutchins G, Nalepa G, Yang FC, Conway SJ, Heinz MG, Stemmer-Rachamimov A, Yates CW, Wade Clapp D. Gehlhausen JR, et al. Among authors: park sj. Hum Mol Genet. 2015 Jan 1;24(1):1-8. doi: 10.1093/hmg/ddu414. Epub 2014 Aug 11. Hum Mol Genet. 2015. PMID: 25113746 Free PMC article.
A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.
Gehlhausen JR, Hawley E, Wahle BM, He Y, Edwards D, Rhodes SD, Lajiness JD, Staser K, Chen S, Yang X, Yuan J, Li X, Jiang L, Smith A, Bessler W, Sandusky G, Stemmer-Rachamimov A, Stuhlmiller TJ, Angus SP, Johnson GL, Nalepa G, Yates CW, Wade Clapp D, Park SJ. Gehlhausen JR, et al. Among authors: park sj. Hum Mol Genet. 2019 Feb 15;28(4):572-583. doi: 10.1093/hmg/ddy361. Hum Mol Genet. 2019. PMID: 30335132 Free PMC article.
PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
Hawley E, Gehlhausen J, Karchugina S, Chow HY, Araiza-Olivera D, Radu M, Smith A, Burks C, Jiang L, Li X, Bessler W, Masters A, Edwards D, Burgin C, Jones D, Yates C, Clapp DW, Chernoff J, Park SJ. Hawley E, et al. Among authors: park sj. Hum Mol Genet. 2021 Aug 12;30(17):1607-1617. doi: 10.1093/hmg/ddab106. Hum Mol Genet. 2021. PMID: 34075397 Free PMC article.
Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.
Staser K, Park SJ, Rhodes SD, Zeng Y, He YZ, Shew MA, Gehlhausen JR, Cerabona D, Menon K, Chen S, Sun Z, Yuan J, Ingram DA, Nalepa G, Yang FC, Clapp DW. Staser K, et al. Among authors: park sj. J Clin Invest. 2013 Jan;123(1):329-34. doi: 10.1172/JCI66167. Epub 2012 Dec 10. J Clin Invest. 2013. PMID: 23221339 Free PMC article.
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, Zhang C, Angus SP, Johnson GL, Packer RJ, Allen JC, Ullrich NJ, Goldman S, Gutmann DH, Plotkin SR, Rosser T, Robertson KA, Widemann BC, Smith AE, Bessler WK, He Y, Park SJ, Mund JA, Jiang L, Bijangi-Vishehsaraei K, Robinson CT, Cutter GR, Korf BR; Neurofibromatosis Clinical Trials Consortium; Blakeley JO, Clapp DW. Fisher MJ, et al. Among authors: park sj. Nat Med. 2021 Jan;27(1):165-173. doi: 10.1038/s41591-020-01193-6. Epub 2021 Jan 13. Nat Med. 2021. PMID: 33442015 Free PMC article. Clinical Trial.
8,457 results